← Back to Search

Biomarker Testing with Standard Treatment for Cervical Cancer

N/A

Recruiting

Led By Denise Fabian, MD

Research Sponsored by Denise Fabian

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months posttherapy

Awards & highlights

Study Summary

This trialtests biomarkers of uterine cervix cancer in women receiving radiochemotherapy and brachytherapy. Blood samples are used to detect cancer markers.

Who is the study for?

This trial is for women with untreated cervical cancer stages IB3 (>4cm), II, III, or IVA. It's not suitable for those who've had other invasive cancers in the last three years (except certain skin cancers and in situ cervical carcinoma) or prior pelvic radiotherapy that could harm normal tissue.Check my eligibility

What is being tested?

The study tests molecular biomarkers in women undergoing standard radiochemotherapy followed by brachytherapy for uterine cervix cancer. Researchers will analyze blood samples to detect specific DNA and tumor cells.See study design

What are the potential side effects?

Since patients receive standard treatments, side effects may include fatigue, nausea, hair loss from chemotherapy; skin irritation and discomfort from radiation; and potential bleeding or infection from sample collection.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months posttherapy

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months posttherapy

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months posttherapy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Biomarker

Side effects data

From 2014 Phase 4 trial • 82 Patients • NCT01835379

12%

Osteomyelitis

Cellulitis

Anaemia

Deep vein thrombosis

Lower GI hermorrhage

GERD

Transient ischemic attack (TIA)

100%

80%

60%

40%

20%

Study treatment Arm

Standard

Oasis

Trial Design

1Treatment groups

Experimental Treatment

Group I: Radiochemotherapy followed by brachytherapyExperimental Treatment1 Intervention

Standard daily radiotherapy plus weekly cisplatin followed by brachytherapy

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Standard

2013

Completed Phase 4

~5340

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

UK Radiopharma AllianceUNKNOWN

Denise FabianLead Sponsor

1 Previous Clinical Trials

20 Total Patients Enrolled

Charles KunosLead Sponsor

1 Previous Clinical Trials

2 Total Patients Enrolled

Media Library

Radiochemotherapy followed by brachytherapy Clinical Trial Eligibility Overview. Trial Name: NCT05462951 — N/A

Cervical Cancer Research Study Groups: Radiochemotherapy followed by brachytherapy

Cervical Cancer Clinical Trial 2023: Radiochemotherapy followed by brachytherapy Highlights & Side Effects. Trial Name: NCT05462951 — N/A

Radiochemotherapy followed by brachytherapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT05462951 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies for participants in this medical trial?

"Clinicaltrials.gov information suggests that this medical trial is actively enrolling participants, with a first posting date of March 1st 2023 and most recent update on April 1st 2023."

Answered by AI

To what extent is the trial participant pool expanding?

"Affirmative, the information on clinicaltrials.gov verifies that this study is currently seeking volunteers. This experiment was initially posted on March 1st 2023 and has been recently revised as of April 1st 2023. 30 participants are being recruited from a single medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer

Denise Fabian 2023. "Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05462951.